The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business update

30 Apr 2007 07:49

ViaLogy PLC30 April 2007 Date: 30 April 2007On behalf of: ViaLogy plc ("ViaLogy" or "the Company") For immediate release ViaLogy PLC Business Update Vialogy SPMTM selected by US Department of Defence for joint experiments todevelop Joint Forces Protection and Base Security Systems London, April 30, 2007 -- ViaLogy PLC (LSE: VIY), announces that its Americansubsidiary, ViaLogy LLC, has been chosen by the US Department of Defence (DoD)to participate in joint experiments to support next-generation Joint ForceProtection Advanced Security (JFPASS) Joint Capabilities TechnologyDemonstration (JCTD). ViaLogy was selected to provide a Command and Controlplatform for the experiments. Recent DoD studies have found that current technologies, as employed, do notprovide a comprehensive, integrated and sustainable Joint Force Protectioncapability. The goal of JFPASS is to address these shortcomings with a potential$60 million combined services project to begin in 2008. The JFPASS JCTD is a joint services (Army, Navy, Air Force and Marines)initiative for integrating tactical systems, sensors and security personnel toprotect forces and over 600 facilities in the US and overseas. NATO and othercoalition partners have similar needs for base and force protection globally. ViaLogy will be providing its SPMTM (Sensor Policy Manager) product for theinternet protocol-enabled sensors and systems to accurately and immediatelyinterpret and disseminate information to pre-selected destinations. The lack ofsuch an effective interoperability between systems has previously been asignificant problem for both the military and public sectors. At a recent integration assessment supporting JFPASS JCTD in the Space and NavalWarfare Systems Centre (SPAWAR), San Diego, CA, ViaLogy successfullydemonstrated interoperability between two disparate operators, NorthropGrumman's Tactical Asset Security System (TASS) and the Joint BattlespaceCommand and Control Station (JBC2S) for unmanned systems. ViaLogy has alsointegrated a Lightweight Chemical Detector (LCD) from Smiths Detection tovalidate the IP-based plug-and-play capabilities of SPMTM. The LCD is part ofthe soldiers' hand-held equipment and is used for checking cargo, personnel orbuildings for chemical warfare agents. ViaLogy's SPMTM product provides a sensor-based policy engine for the rapiddetection, analysis and transmission of information. It exploits internetprotocol and patented signal processing to deliver interoperability to sensor,video and network sub-systems. Of major importance to potential users of SPMTM are its reliability,adaptability and affordability. "The product is designed for scaleableimplementation involving hundreds and even thousands of sensors," said Dr.Sandeep Gulati, ViaLogy's Chief Technology Officer. "JFPASS requirements presentan ideal opportunity for SPMTM. The technology thrives on the unexpected and, inthe event of a major incident, plays a vital role in detection and effectivedamage control." Previously, as NASA's Jet Propulsion Laboratory PrincipalScientist for sensor fusion, Dr. Gulati was extensively involved with sensorintensive command and control systems. ViaLogy CEO, Mr. Shah Talukder stated: "Higher demand for commercialoff-the-shelf products will shift procurement from project-centric toproduct-centric acquisition of technology. This will drive down project costsand timelines as it does in private sector procurement." Mr. Talukder who, prior to joining ViaLogy, developed the vision, strategy androad map for Cisco's Interoperability and Collaboration System (IPICS), added: "By delivering comprehensive sensor, video and tactical interoperability in anetwork-centric platform we believe SPM product will be able to meet JFPASS JCTDrequirements and play an integral part in the joint forces security project." For further information please contact: ViaLogy Shah Talukder, CEO - US +1 626-296-6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 Seymour Pierce Limited (NOMAD)Mark Percy +44 (0)20 7107 8000 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.